Core Insights - Kura Oncology and Kyowa Kirin announced positive pivotal results from the KOMET-001 Phase 2 trial of ziftomenib for relapsed/refractory NPM1-mutant AML patients, with a complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 23% [1][3][2] - The trial demonstrated consistent efficacy across various pre-specified subgroups, indicating the potential of ziftomenib as a treatment option for heavily pre-treated patients [1][4][2] - Ziftomenib has a favorable safety profile, with limited myelosuppression and a low discontinuation rate due to treatment-related adverse events [1][5][7] Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, with ziftomenib being the first investigational therapy to receive Breakthrough Therapy Designation from the FDA for R/R NPM1-m AML [9] - The company has a strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, with ongoing clinical trials evaluating its efficacy in combination with current standards of care [9][10] Clinical Trial Details - The KOMET-001 Phase 2 trial included 92 adult patients with a median age of 69, with 33% having received three or more prior lines of therapy [2][3] - Among the patients achieving CR/CRh, 63% were minimal residual disease (MRD)-negative, highlighting the treatment's potential effectiveness [3][4] Safety and Tolerability - The safety profile of ziftomenib showed that treatment-related adverse events led to discontinuation in only 3% of patients, with differentiation syndrome being the most common adverse event [5][6][7] - The absence of clinically significant QTc prolongation and effective management of differentiation syndrome further support ziftomenib's favorable benefit-risk profile [7][6] Future Outlook - The FDA has set a PDUFA target action date of November 30, 2025, for the New Drug Application (NDA) of ziftomenib, indicating a potential first approval for a once-daily oral menin inhibitor for this patient population [1][2] - Kura Oncology is hosting a virtual investor event to discuss the trial results and future plans for ziftomenib [8]

Company resumed trading under its existing symbol "MINM" HONG KONG, June 2, 2025 /PRNewswire/ -- FiEE, Inc. (NASDAQ:MINM) ("FiEE, Inc." or the "Company"), a technology company integrating IoT, connectivity and AI to redefine brand management solutions in the digital era, commenced the trading of its common stock on Monday, June 2, 2025 on the Nasdaq Capital Market under the ticker symbol "MINM".With the vision of growing Key Opinion Leaders ("KOLs") in the market, FiEE, Inc. is currently strategically trans ...

SYDNEY, June 02, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Mark Gossington as a Senior Managing Director in the Risk & Investigations practice within the firm’s Forensic and Litigation Consulting segment. Mr. Gossington, who is based in Sydney, brings more than 25 years of experience leading complex risk engagements and remediation programmes that have helped companies strengthen resilience under regulatory scrutiny, recover from misconduct issues and build ...

Group 1 - CNH Industrial N.V. announced the pricing of Cdn$500 million in aggregate principal amount of 3.75% notes due June 5, 2029, with an issue price of 100.00% [1] - The offering is expected to close on June 5, 2025, subject to customary closing conditions [1] - The net proceeds from the offering will be used for working capital and other general corporate purposes, including the purchase of receivables and repayment of indebtedness [2] Group 2 - The notes are senior unsecured obligations and will pay interest semi-annually starting December 5, 2025 [3] - The notes will be guaranteed by CNH Industrial Capital LLC, CNH Industrial Capital America LLC, and New Holland Credit Company, LLC, all of which are indirect wholly owned subsidiaries of CNH Industrial N.V. [3] - The securities offered in the private placement have not been qualified for sale to the public under applicable securities laws in Canada [4] Group 3 - The securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States without an effective registration statement or applicable exemption [5] - This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities [6] - CNH Industrial Capital LLC primarily underwrites and manages financing products for customers and dealers of CNH Industrial North America [7]

Leadership Transition - Matthew Hayden will transition from a board director role to a newly created position as Entrepreneur in Residence effective June 30, 2025, leveraging his three decades of experience to support early-stage disruptive technology companies [2][3] - Dan Torpey has been appointed Chair of the Audit Committee effective February 13, 2025, bringing 24 years of experience as an Assurance Partner at Ernst & Young LLP, enhancing MDB's governance and operational rigor [3] Company Strategy - These leadership transitions reflect MDB's commitment to building a world-class leadership team to support its strategy of launching and scaling transformational technology ventures [4] - MDB Capital Holdings focuses on launching "Big Ideas" into valuable public companies through community-driven financings of pre-revenue, early-stage disruptive technology companies, primarily via early public offerings on NASDAQ [5]

Core Viewpoint - Petrus Resources Ltd. has declared a monthly dividend of $0.01 per share, payable on June 30, 2025, to shareholders of record on June 16, 2025, which is designated as an eligible dividend for Canadian income tax purposes [1] Group 1: Dividend Information - The monthly dividend amount is set at $0.01 per share [1] - The dividend payment date is June 30, 2025, with a record date of June 16, 2025 [1] Group 2: Dividend Reinvestment Plan (DRIP) - Petrus offers a Dividend Reinvestment Plan (DRIP) that allows eligible shareholders to reinvest cash dividends into additional common shares at a 3% discount from the market price [2] - Participation in the DRIP is optional for eligible shareholders [2] Group 3: Enrollment in DRIP - Registered shareholders must submit a completed enrollment form to Odyssey Trust Company by 4:00 p.m. Calgary time on the 5th business day before the dividend record date to participate in the DRIP [3] - Beneficial shareholders should contact their broker to determine eligibility and obtain enrollment instructions [3] - Participation may be restricted for shareholders not residing in Canada [3] Group 4: Company Overview - Petrus Resources Ltd. is a public Canadian oil and gas company focused on property exploitation, strategic acquisitions, and risk-managed exploration in Alberta [5]

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Angus Gold Inc. (TSX-V: GUS | OTC: ANGVF) (“Angus” or the “Company”) reminds shareholders of its upcoming special meeting (the “Special Meeting”) to vote on the proposed arrangement transaction (the “Arrangement”) with Wesdome Gold Mines Ltd. (“Wesdome”), announced on April 7, 2025 and to be held on June 19, 2025. Shareholders must submit proxies by 5:00 p.m. (Toronto time) on June 17, 2025. Angus encourages all shareholders to vote as soon as possible. Following a ...

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (TSX: FFH and FFH.U) (“Fairfax”) announces that it has declared the following quarterly dividends per share on its preferred shares: Series of Preferred SharesDividend (C$)Payment DateRecord DateSeries G0.185125June 30, 2025June 13, 2025Series H0.33645June 27, 2025 <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle; text-align: left; ...

EDMONTON, Alberta, June 02, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, today provided a corporate update and announced that it has filed its annual audited financial statements for the year ended January 31, 2025, Management’s Discussion and Analysis and related filings on SEDAR+ (www.sedarplus.ca). The Company report ...

CALGARY, Alberta, June 02, 2025 (GLOBE NEWSWIRE) -- News Release – TC Energy Corporation (TSX:TRP) (NYSE:TRP) (TC Energy) today announced that it does not intend to exercise its right to redeem its Cumulative Redeemable First Preferred Shares, Series 3 (Series 3 Shares) and Cumulative Redeemable First Preferred Shares, Series 4 (Series 4 Shares) on June 30, 2025. As a result, subject to certain conditions: (a) the holders of Series 3 Shares have the right to choose one of the following options with regard t ...